ImmunyX

ImmunyX is a private biotechnology company developing targeted therapies that modulate neutrophil function in chronic inflammatory diseases and cancer. The company is built around a neutrophil-targeting nanoparticle delivery platform designed to improve drug localization to neutrophils and reduce systemic toxicity. Its disclosed internal pipeline includes preclinical programs for inflammatory bowel disease and chronic obstructive pulmonary disease, and the company presents itself as pursuing first-in-class neutrophil-modifying therapeutics. ImmunyX also markets its platform as a partnering solution for pharma companies seeking better delivery of existing or pipeline immune-modulating agents. The company operates from New York and has scientific roots in Israel and technology originating from the Hebrew University.